|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Nadolol#Patient Counseling Information]] |
| {{Nadolol}}
| |
| {{CMG}}; {{AE}} {{AZ}}
| |
| | |
| ==Information for Patients==
| |
| | |
| Patients, especially those with evidence of coronary artery insufficiency, should be warned against interruption or discontinuation of nadolol therapy without the physician's advice. Although [[cardiac failure]] rarely occurs in properly selected patients, patients being treated with beta-adrenergic blocking agents should be advised to consult the physician at the first sign or symptom of impending failure. The patient should also be advised of a proper course in the event of an inadvertently missed dose.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = INDERAL LA (PROPRANOLOL HYDROCHLORIDE) CAPSULE, EXTENDED RELEASE [AKRIMAX PHARMACEUTICALS, LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c2e709d2-96a2-41ea-b5e9-9ce4ccb91f59 | publisher = | date = |accessdate = }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Drugs]]
| |